Progression-free survival of NLPHL and cHL patients treated within the HD16 and HD17 studies. (A) PFS of patients with NLPHL (red) and those with cHL (blue) treated in the HD16 study. (B) PFS of patients with NLPHL (red) and those with cHL (blue) treated in the HD17 study.